Cargando…

CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma

OBJECTIVE: We sought to characterize the variability of CCNE1 amplification among metastatic sites of CCNE1 amplified high grade serous carcinoma (HGSC) cases to investigate the feasibility of targeting this alteration for therapeutic purposes. METHODS: Patients with CCNE1 amplified HGSC who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margolis, Benjamin, Dao, Fanny, Licciardi, Michael, Misirlioglu, Selim, Olvera, Narciso, Ramaswami, Sitharam, Levine, Douglas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391017/ https://www.ncbi.nlm.nih.gov/pubmed/34485660 http://dx.doi.org/10.1016/j.gore.2021.100850

Ejemplares similares

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
por: Chan, Angela MY, et al.
Publicado: (2020)

CCNE1 Amplification and Centrosome Number Abnormality in Serous Tubal Intraepithelial Carcinoma- Further Evidence Supporting its Role as a Precursor of Ovarian High-Grade Serous Carcinoma
por: Kuhn, Elisabetta, et al.
Publicado: (2016)

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022)

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
por: NAKAYAMA, KENTARO, et al.
Publicado: (2015)

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
por: Gallo, David, et al.
Publicado: (2022)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer
por: Noske, Aurelia, et al.
Publicado: (2016)

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics
por: Noack, Sabrina, et al.
Publicado: (2018)

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
por: Zhao, Zi-Ming, et al.
Publicado: (2019)

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
por: Gorski, Justin W., et al.
Publicado: (2020)

Use of a gelatin-thrombin hemostatic matrix in obstetrics and gynecological surgery
por: Mısırlıoğlu, Selim, et al.
Publicado: (2018)

Prognostic Values of CCNE1 Amplification and Overexpression in Cancer Patients: A Systematic Review and Meta-analysis
por: Zhao, Haiyue, et al.
Publicado: (2018)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
por: Clarfield, Lauren, et al.
Publicado: (2022)

WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers
por: Goehring, Liana, et al.
Publicado: (2021)

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
por: Guerrero-Zotano, Ángel, et al.
Publicado: (2023)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
por: Kim, Olga, et al.
Publicado: (2020)

Amplification of The ch19p13.2 NACC1 Locus in Ovarian High-grade Serous Carcinoma
por: Shih, Ie-Ming, et al.
Publicado: (2011)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type
por: Jelinic, Petar, et al.
Publicado: (2016)

Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
por: Zhang, Shuang, et al.
Publicado: (2019)

Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
por: Davidson, Ben, et al.
Publicado: (2023)

Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2
por: Liang, Yuan, et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma
por: Jena, Saubhagya Kumar, et al.
Publicado: (2015)

PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer
por: Jones, Wendell, et al.
Publicado: (2022)

Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study
por: Ayhan, Ali, et al.
Publicado: (2018)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Oncogenes in high grade serous adenocarcinoma of the ovary
por: Manasa, Pacharla, et al.
Publicado: (2020)

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
por: Rhyasen, Garrett W., et al.
Publicado: (2018)

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer
por: van Wagensveld, Lilian, et al.
Publicado: (2022)

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report
por: Catteau, Xavier, et al.
Publicado: (2021)

Metastatic serous endometrial carcinoma to the ureter
por: Sahl, Jessa W., et al.
Publicado: (2021)

Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma
por: Barrie, Allison M., et al.
Publicado: (2019)

Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
por: Davidson, Ben, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tobk4fd2l1feknvahq62r2h9kc